Cargando…

PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension

BACKGROUND: Liver-related deaths represent the leading cause of mortality among patients with HIV/HCV-co-infection, and are mainly related to complications of fibrosis and portal hypertension. In this study, we aimed to evaluate the structural changes by the assessment of extracellular matrix (ECM)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Christian, Leeming, Diana J., Mandorfer, Mattias, Byrjalsen, Inger, Schierwagen, Robert, Schwabl, Philipp, Karsdal, Morten A., Anadol, Evrim, Strassburg, Christian P., Rockstroh, Jürgen, Peck-Radosavljevic, Markus, Møller, Søren, Bendtsen, Flemming, Krag, Aleksander, Reiberger, Thomas, Trebicka, Jonel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180447/ https://www.ncbi.nlm.nih.gov/pubmed/25265505 http://dx.doi.org/10.1371/journal.pone.0108544

Ejemplares similares

Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection
por: Jansen, Christian, et al.
Publicado: (2015)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS
por: Jansen, Christian, et al.
Publicado: (2014)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension
por: Leeming, D J, et al.
Publicado: (2013)

microRNA‐200a: A stage‐dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients
por: Austermann, Christian, et al.
Publicado: (2017)

Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats
por: Schierwagen, Robert, et al.
Publicado: (2013)

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
por: Chromy, David, et al.
Publicado: (2017)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension
por: Trebicka, Jonel, et al.
Publicado: (2013)

Etiology and Complications of Portal Vein Thrombosis
por: Trebicka, Jonel, et al.
Publicado: (2014)

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients
por: Anadol, Evrim, et al.
Publicado: (2018)

High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal
por: Kjærgaard, Maria, et al.
Publicado: (2017)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites
por: Mandorfer, Mattias, et al.
Publicado: (2014)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART
por: Dold, Leona, et al.
Publicado: (2019)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?
por: Mohr, Raphael, et al.
Publicado: (2015)

Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV
por: Dold, Leona, et al.
Publicado: (2023)

PRO‐C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol‐related liver disease
por: Madsen, Bjørn S., et al.
Publicado: (2021)

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Mandorfer, M., et al.
Publicado: (2018)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Role of circulating angiogenin levels in portal hypertension and TIPS
por: Queck, Alexander, et al.
Publicado: (2021)

A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis
por: Schierwagen, Robert, et al.
Publicado: (2020)

MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis
por: Lutz, Philipp, et al.
Publicado: (2017)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis
por: Mohr, Raphael, et al.
Publicado: (2018)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2016)

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
por: Schwabl, Philipp, et al.
Publicado: (2018)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation
por: Karsdal, MA, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_5bau76gle20q7brat09ajum443